Cue Biopharma Stock Short Ratio
| CUE Stock | USD 2.18 0.10 4.81% |
Cue Biopharma fundamentals help investors to digest information that contributes to Cue Biopharma's financial success or failures. It also enables traders to predict the movement of Cue Stock. The fundamental analysis module provides a way to measure Cue Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cue Biopharma stock.
Cue | Short Ratio |
Cue Biopharma Company Short Ratio Analysis
Cue Biopharma's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Cue Biopharma Short Ratio | 17.99 X |
Most of Cue Biopharma's fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cue Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cue Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Cue Biopharma is extremely important. It helps to project a fair market value of Cue Stock properly, considering its historical fundamentals such as Short Ratio. Since Cue Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cue Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cue Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Cue Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, Cue Biopharma has a Short Ratio of 17.99 times. This is 361.28% higher than that of the Biotechnology sector and 142.78% higher than that of the Health Care industry. The short ratio for all United States stocks is notably lower than that of the firm.
Cue Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cue Biopharma's direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cue Biopharma could also be used in its relative valuation, which is a method of valuing Cue Biopharma by comparing valuation metrics of similar companies.Cue Biopharma is currently under evaluation in short ratio category among related companies.
Cue Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Cue Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cue Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cue Biopharma's value.| Shares | Bank Of America Corp | 2023-12-31 | 266.2 K | Advisory Research Inc | 2023-12-31 | 257.2 K | Stifel Financial Corp | 2023-12-31 | 194 K | Nuveen Asset Management, Llc | 2023-12-31 | 191.5 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 164.7 K | Carlson Capital Lp | 2023-12-31 | 120 K | Goldman Sachs Group Inc | 2023-12-31 | 116.6 K | Bank Of New York Mellon Corp | 2023-12-31 | 109.4 K | Sigma Planning Corp | 2023-12-31 | 108.9 K | Slate Path Capital Lp | 2023-12-31 | 2.4 M | Blackrock Inc | 2023-12-31 | 2.3 M |
Cue Fundamentals
| Return On Equity | -0.99 | ||||
| Return On Asset | -0.43 | ||||
| Operating Margin | (7.51) % | ||||
| Current Valuation | 72.22 M | ||||
| Shares Outstanding | 48.64 M | ||||
| Shares Owned By Insiders | 2.97 % | ||||
| Shares Owned By Institutions | 33.59 % | ||||
| Number Of Shares Shorted | 4.78 M | ||||
| Price To Earning | (2.17) X | ||||
| Price To Book | 2.28 X | ||||
| Price To Sales | 15.51 X | ||||
| Revenue | 5.49 M | ||||
| Gross Profit | 1.25 M | ||||
| EBITDA | (48.56 M) | ||||
| Net Income | (50.73 M) | ||||
| Cash And Equivalents | 66.13 M | ||||
| Cash Per Share | 1.87 X | ||||
| Total Debt | 14.7 M | ||||
| Debt To Equity | 0.33 % | ||||
| Current Ratio | 8.29 X | ||||
| Book Value Per Share | 0.79 X | ||||
| Cash Flow From Operations | (39.96 M) | ||||
| Short Ratio | 17.99 X | ||||
| Earnings Per Share | (1.11) X | ||||
| Target Price | 9.4 | ||||
| Number Of Employees | 53 | ||||
| Beta | 2.01 | ||||
| Market Capitalization | 106.04 M | ||||
| Total Asset | 61.53 M | ||||
| Retained Earnings | (301.19 M) | ||||
| Working Capital | 34.37 M | ||||
| Current Asset | 42.21 M | ||||
| Current Liabilities | 3.38 M | ||||
| Net Asset | 61.53 M |
About Cue Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cue Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cue Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cue Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Cue Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cue Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cue Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Cue Stock
| 0.7 | IMNN | Imunon Inc Financial Report 9th of May 2024 | PairCorr |
| 0.57 | HCWB | HCW Biologics | PairCorr |
| 0.47 | NVO | Novo Nordisk AS | PairCorr |
The ability to find closely correlated positions to Cue Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cue Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cue Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cue Biopharma to buy it.
The correlation of Cue Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cue Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cue Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cue Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Cue Biopharma Piotroski F Score and Cue Biopharma Altman Z Score analysis. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Cue Stock analysis
When running Cue Biopharma's price analysis, check to measure Cue Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Biopharma is operating at the current time. Most of Cue Biopharma's value examination focuses on studying past and present price action to predict the probability of Cue Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Biopharma's price. Additionally, you may evaluate how the addition of Cue Biopharma to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Cue Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.11) | Revenue Per Share 0.12 | Quarterly Revenue Growth 11.06 | Return On Assets (0.43) | Return On Equity (0.99) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.